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Abstract: Cardiac injury triggers cellular responses involving both cardiomyocytes and nonmuscle cells
to process cardiac structural remodeling. End-stage renal disease (ESRD), despite conventional dialy-
sis, is associated with adverse cardiac remodeling and increased cardiovascular events. Intensification of
hemodialysis with nocturnal home hemodialysis (NHD; five sessions per week; 6–8 hours per treatment)
was associated with regression of left ventricular hypertrophy and downregulation of genes in apoptosis
and fibrosis. In this pilot study, we hypothesize that NHD achieves its cardiac effects in part through at-
tenuation of innate immune activation resulting in amelioration of cardiomyocytes apoptosis and fibrosis.
Eight patients (4M:4F; age, 59 ± 9 years) with ESRD were studied. Half of the cohort was converted to
NHD, whereas the rest of the patients were maintained on conventional hemodialysis (CHD). At base-
line, CHD was associated with an increase in cardiomyocyte apoptosis detected by flow cytometry using
Annexin V (mean fluorescence index in CHD and in normal control is 1.00 ± 0.05 vs. 0.66 ± 0.01, p
< 0.05). After conversion to NHD, cardiomyocyte apoptosis was reduced compared with baseline CHD
situation (p < 0.05) and approached that of normal control (0.59 ± 0.09 vs. 0.66 ± 0.01, p > 0.05).
The CHD serum was associated with a coordinated augmentation innate immunity pathway, significantly
increasing myeloid differentiation factor-88 and interleukin-1 receptor–associated kinase-4; NHD was able
to reduce their levels. Heat shock protein 60 was augmented during CHD condition and fell after NHD.
In addition, CHD increased fibroblast proliferation and myofibroblast transformation. Uremia is asso-
ciated with activation of common innate immune signaling pathways leading to fibrosis and apoptosis.
Amelioration of uremic clearance by NHD may attenuate this pathological signaling cascade.
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ASAIO Journal 2015 Pilot Study
Cardiac injury triggers cellular responses involving both car-
diomyocytes and nonmuscle cells to process cardiac structural 
remodeling. End-stage renal disease (ESRD), despite conven-
tional dialysis, is associated with adverse cardiac remodel-
ing and increased cardiovascular events. Intensification of 
hemodialysis with nocturnal home hemodialysis (NHD; five 
sessions per week; 6–8 hours per treatment) was associated 
with regression of left ventricular hypertrophy and downregu-
lation of genes in apoptosis and fibrosis. In this pilot study, 
we hypothesize that NHD achieves its cardiac effects in part 
through attenuation of innate immune activation resulting in 
amelioration of cardiomyocytes apoptosis and fibrosis. Eight 
patients (4M:4F; age, 59 ± 9 years) with ESRD were studied. 
Half of the cohort was converted to NHD, whereas the rest 
of the patients were maintained on conventional hemodialy-
sis (CHD). At baseline, CHD was associated with an increase 
in cardiomyocyte apoptosis detected by flow cytometry using 
Annexin V (mean fluorescence index in CHD and in normal 
control is 1.00 ± 0.05 vs. 0.66 ± 0.01, p < 0.05). After conver-
sion to NHD, cardiomyocyte apoptosis was reduced com-
pared with baseline CHD situation (p < 0.05) and approached 
that of normal control (0.59 ± 0.09 vs. 0.66 ± 0.01, p > 0.05). 
The CHD serum was associated with a coordinated augmen-
tation innate immunity pathway, significantly increasing 
myeloid differentiation factor-88 and interleukin-1 receptor–
associated kinase-4; NHD was able to reduce their levels. 
Heat shock protein 60 was augmented during CHD condi-
tion and fell after NHD. In addition, CHD increased fibroblast 
proliferation and myofibroblast transformation. Uremia is 
associated with activation of common innate immune signal-
ing pathways leading to fibrosis and apoptosis. Amelioration 
of uremic clearance by NHD may attenuate this pathological 
signaling cascade. ASAIO Journal 2015; 61:613–619.
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All forms of cardiac injury trigger cellular responses involving 
both cardiomyocytes and nonmuscle cells leading to cardio-
myocyte death, cardiac fibroblast proliferation, and fibrosis.1,2 
Cardiomyocyte death has been recently identified as an impor-
tant novel marker of cardiac pathologies including heart fail-
ure, left ventricular hypertrophy (LVH), myocardial infarction, 
and ischemia/reperfusion injury.3,4 Indeed, the extent of cardio-
myocyte damage was shown to be an independent predictor 
of clinical outcomes in patients with dilated cardiomyopathy.5
Cardiovascular disease continues to be the leading cause of 
death in patients with end-stage renal disease (ESRD) undergoing 
conventional hemodialysis (CHD) three times a week. Intensive 
home nocturnal home hemodialysis (NHD; 5–6 times per week, 
6–8 hours per session) has been shown to be associated with regres-
sion of LVH6 and other cardiovascular surrogate outcomes.7–10 
Recently, our team reported that intensification of hemodialysis 
dose was also associated with a coordinated downregulation of 
genes that are responsible for apoptosis and fibrosis (cyclin-depen-
dent kinase inhibitor 1A [Cdkn1a] and cyclin-dependent kinase 
inhibitor 1C [Cdkn1c]), Fas, and Bcl2-associated X protein (Bax).11 
In this pilot study, we aim to examine the pathway by which NHD 
may attenuate the process of cardiac injury.
We hypothesize that soluble substances in the uremic plasma 
from CHD patients exposed to cardiomyocytes will trigger an 
innate immune response resulting in apoptosis of cardiomyo-
cytes, and conversion from CHD to NHD will decrease the 
extent of innate immunity–mediated cardiomyocytes apopto-
sis. In contrast, patients maintained on CHD will be associated 
with similar degree of cardiomyocyte apoptosis. The present 
exploratory study will form the basis for a comparative trial.
Methods
This protocol was approved by the Research Ethics Board 
of the Toronto General Hospital, University Health Network, 
Toronto, Canada, and conformed to the standards established 
by the Declaration of Helsinki. Medically stable ESRD patients 
(age between 18–85 years) who have received a minimum of 3 
months of CHD were invited to participate in this study. None 
of the patients had any acute illness, hospitalization, or symp-
tomatic cardiovascular disease (including congestive heart 
failure and acute coronary syndrome). Normal subjects were 
also recruited. Written informed consent was obtained from 
each patient. Pregnant patients were excluded. Herein, we will 
describe the clinical aspects of the protocol, followed by the 
in vitro experimental details.
Subjects
Subjects included consecutive eligible patients who were 
maintained on CHD or being converted from CHD to NHD at 
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the University Health Network. Patient demographic information, 
such as age, gender, ethnicity, etiology of ESRD, and comorbid 
conditions, was prospectively collected into a computerized clin-
ical database. Medications were recorded. Clinical assessment, 
including weight, height, and blood pressure measurements, was 
performed at baseline and monthly after conversion to NHD. All 
blood pressure measurements were made at the patients’ home 
using a calibrated blood pressure cuff after 5 minutes of rest at 
the sitting position. Biochemical and hematological parameters 
(complete blood count, urea, creatinine, albumin, calcium, phos-
phate, and parathyroid hormone) were obtained monthly during 
the same time intervals. Baseline and subsequent 1 year blood 
samples were collected predialysis at the same time of day. In the 
case of NHD, a minimum of 4 hours after the regular NHD session 
was ensured to approximate steady-state condition. Eight patients 
(4M:4F; age, 59 ± 9 years) with ESRD were studied. Description of 
our study patient cohort is outlined in Table 1.
Dialysis Protocol
CHD patients received hemodialysis for 4 hours 3 times per 
week by similar vascular access. A blood flow rate of 400 ml 
per minute, a dialysate flow rate of 500–750 ml per minute, and 
F80 polysulfone dialyzers (Fresenius Medical Care, Lexington, 
MA) were used. The NHD patients received hemodialysis at 
home for 6–8 hours, 5–6 nights per week. Vascular access was 
achieved through either a long-term internal jugular catheter 
(Uldall Catheter, Cook Critical Care, Bloomington, IN) or an 
arteriovenous fistula. Dialysate flow rate of 350 ml per minute 
and blood flow rate of 200–300 ml per minute was used. F80 
polysulfone dialyzers (Fresenius Medical Care) or Xenium dia-
lyzers (Baxter, Chicago, IL) were used. Unfractionated heparin 
was used for anticoagulation on CHD and NHD.
Dialysis dose per treatment was estimated by equilibrated 
Kt/V (eKt/V) as described by Daugirdas et al.12: eKt/V = spKt/V 
− 0.6(spKt/V)/t + 0.03, where spKt/V = single-pool Kt/V, 
K = delivered clearance, t = dialysis time, and V = urea distri-
bution volume.  Single-pool Kt/V was determined using blood 
urea reduction ratio.13
Neonatal Cell Culture Preparation
Ventricular myocytes and cardiac fibroblast were isolated 
from 2-day-old neonatal C57/B6 mice. In brief, neonatal mouse 
myocytes were isolated and cultured as described previously.14,15  
A single litter of 1- to 2-day-old mice was used for each experi-
ment. Pups were killed by cervical dislocation, and the hearts were 
removed quickly into filter-sterilized buffer. By using aseptic tech-
nique, atria and blood vessels were removed, and the ventricles 
were minced. Ventricular tissue was dissociated at room tempera-
ture (22–24°C) with trypsin and gentle mechanical agitation. Cells 
were collected in fetal calf serum (FCS, Gibco, Grand Island, NY). 
When dissociation was complete, the cell suspension was centri-
fuged, washed once, and resuspended in culture medium (Dul-
becco’s Modified Eagle Medium: HAM F-12 [Gibco], 1:1, 10% 
v/v FCS; penicillin/streptomycin, 50 unit/ml). After preplating, 
cardiomyocytes were collected and plated in the laminin-coated 
6-well culture dishes (Nunc, Thermo Scientific, USA) at a density 
of 3 × 105 viable cells/ml (as determined by trypan blue staining) 
in culture medium supplemented with 5-bromo-2-deoxyuridine 
(0.1 mM; Sigma-Aldrich Co LLC). Cells were incubated at 37°C in 
a humidified atmosphere of 1.5% Co2. After 24 hours in culture, 
the medium was replaced by serum-free medium, and 24 hours 
after serum starvation, each cell groups were treated with 10% 
human plasma (under CHD, NHD, or normal conditions) or with 
fetal bovine serum as a control.
Apoptosis and Fibroblasts Proliferation Assessment Using 
Flow Cytometry
To quantify apoptosis, cells were washed with cold 1x phos-
phate-buffered saline twice and resuspended in 1x Annexin V 
Table 1.  Demographic and Clinical Characteristics
Variable ESRD
N 8
Age (yr) 59 ± 9
Gender (M:F) 4:4
Etiology of ESRD
  Glomerular disease 1
  HTN 2
  Type 2 diabetes 3
  PCKD 1
  Systemic lupus erythematosus 1
Diabetes (%) 50
Antihypertensive medications (%)
  ACEI or ARB 63
  Calcium channel blocker 40
  β-Blocker 63
Vascular access
  Arteriovenous fistula 4
  Central venous catheter 4 
ACEI, angiotensin-converting enzyme inhibitors; ARB, angioten-
sin receptor blockers; ESRD, end-stage renal disease; F, female; 
HTN, hypertension; M, male; PCKD, polycystic kidney disease.
Table 2.  Changes in Biochemical Parameters
Control Group Baseline Control Group Final NHD Group baseline NHD Group Final
Variables (N) 4 4 4 4
Albumin (g/L) 36.2 ± 1.9 36.0 ± 1.9 36.2 ± 2.2 37.5 ± 1.3
Phosphate (mmol/L) 1.44 ± 0.4 1.67 ± 0.1 1.49 ± 0.43 1.38 ± 0.15
PTH (nmol/L) 16.0 ± 7.2 38.6 ± 18.8 27.9 ± 13.0 31.6 ± 10.8
Systolic blood pressure (mmHg) 139 ± 7 140 ± 16 139 ± 9 145 ± 10
Diastolic blood pressure (mmHg) 72 ± 7 73 ± 7 70 ± 4 69 ± 3
Sodium (mmol/L) 135 ± 2 138 ± 1 137 ± 2 135 ± 2
Number of antihypertensive 
medications
2 ± 1 2 ± 1 2 ± 1.4 1 ± 1
NHD, nocturnal home hemodialysis; PTH, parathyroid hormone.
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binding buffer. Staining with fluorescein isothiocyanate–con-
jugated Annexin V was performed according to commercial 
instruction (Biolegend, San Diego, CA). To evaluate the prolif-
eration of cardiac fibroblast, we plated cardiac fibroblast cells in 
3 × 105/well in 6 well plates. Cells were allowed to grow over-
night and were treated with 0.1 μM carboxyfluorescein diace-
tate succinimidyl ester (CFSE, CellTrace CFSE Cell Proliferation 
Kit, Molecular Probes) for 30 minutes at 37°C in 5% carbon 
dioxide. Cells were washed with five volumes of medium for 
three times. The cell preparation were treated by different groups 
of patients’ plasma for 24 hours and then harvested. Carboxy-
fluorescein diacetate succinimidyl ester diffused passively into 
cells. Fibroblasts were labeled through the reaction of succin-
imidyl ester group and intracellular amines, forming fluorescent 
conjugates and analyzed using a flow cytometer.
Reverse Transcription and Real-Time Quantitative PCR
Total RNA was isolated from neonate cardiomyocytes as 
described earlier after treatment with 10% human plasma 
(under CHD and NHD conditions; n = 3 for each group). 
Reverse transcription was performed using Superscript II (Invi-
trogen, CA) according to the manufacturer’s instruction. Gene 
expression levels were quantified by real-time polymerase 
chain reaction (PCR). All reactions were run in triplicates. The 
primers used for this study are shown in Supplemental Table 
1 (see Supplemental Digital Content 1, http://links.lww.com/
ASAIo/A66). The ratio of the level of each gene measured to 
GAPDH was estimated with the ∆CT (CtTaget − CtGAPDH) method. 
The relative gene expression (fold change with respect to base-
line) was estimated with the 2-∆∆CT method.16
Immunoblotting
Protein levels were examined by immunoblotting as 
described previously.16 Primary antibodies were purchased 
from Santa Cruz Biotechnology (Dallas, TX; GAPDH, α-smooth 
muscle [SM] actin), Cell Signaling (Danvers, MA; myeloid 
differentiation factor-88 [MyD88] and interleukin-1 recep-
tor–associated kinase-4 [IRAK-4], heat shock protein [Hsp]: 
Hsp27, Hsp60, Hsp70, and Hsp90), Stressgen (San Diego, CA; 
tumor necrosis factor receptor–associated factor 6 [Traf6], and 
R & D Systems Inc. (Minneapolis, MN; fibroblast growth factor 
[FGF] 23). Equal amounts of protein (20–50 μg) were loaded 
in each lane of 4–20% Tris-glycine gel (Novex, Invitrogen, CA). 
The bands were analyzed by using the Quantity one software 
(Hercules, CA) and normalized by GAPDH. The results from 
each group of experiment were described as the number of 
fold changes relative to baseline levels.
Data Analysis
Descriptive data are presented as mean ± SE unless other-
wise indicated. The primary outcome measure was the within-
subject paired difference in gene expression before and after 
conversion from CHD to NHD. Secondary outcomes included 
between-subject differences in gene expression. Differentially 
expressed genes were identified as described before and after 
conversion to NHD. Mann-Whitney U test was used for com-
parison of continuous variables between two groups. Analysis 
of variance was used for multiple comparisons of a continu-
ous variable among four groups of subjects. Spearman’s cor-
relation was used to investigate potential associations between 
variables of interest. All statistical tests were two tailed with a p 
value less than 0.05 taken to indicate significance. SPSS version 
10 (SPSS Inc., Chicago, IL) was used for all statistical analyses.
Figure 1. Neonate cardiomyocyte apoptosis detected by flow cytometry using Anexin V in different groups. Left: A representative figure of 
flow cytometry. Right: Quantification by mean fluorescence index. *p < 0.05; #p < 0.01. FCS, fetal calf serum; SE, standard error.
Figure 2. Photomicrograph of cardiomyocytes in culture. A: Con-
ventional hemodialysis condition (baseline). B: Conventional hemo-
dialysis condition (1 year). C: Nocturnal hemodialysis condition.
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Results
Eight patients (4M:4F; age, 59 ± 9 years) with ESRD were 
studied. Their comorbid conditions were listed in Table 1. 
Ninety percent of our study population had a diagnosis of 
hypertension and was prescribed antihypertensive medica-
tions. Half of the cohort was converted to NHD, whereas the 
rest of the patients were maintained on CHD. After conversion 
to NHD, sessional Kt/V increased from 1.20 ± 0.2 to 2.20 ± 0.2, 
p < 0.05. Standardized weekly Kt/V increased from 2.20 ± 0.2 
to 5.50 ± 0.5, p < 0.05 in the NHD cohort, whereas it remained 
unchanged in the CHD patients. There was no between-group 
differences in either baseline or follow-up values in blood 
pressure, hemoglobin, phosphate, or albumin (Table 2).
NHD Was Associated with Reductions in 
Cardiomyocyte Apoptosis and Fibroblast
At baseline, CHD was associated with an increase in cardio-
myocyte apoptosis detected by flow cytometry using Anexin 
V (Figure 1). Mean fluorescence index in CHD and in normal 
control was 1.00 ± 0.05 vs. 0.66 ± 0.01, respectively, p = 0.01). 
After conversion to NHD for 1 year, cardiomyocyte apoptosis 
(0.59 ± 0.09) was reduced compared with baseline CHD con-
dition (p = 0.02 and p < 0.05) and approached that of normal 
control (p = 0.69). In contrast, cardiomyocyte apoptosis did 
not change at baseline and after 1 year of CHD. Qualitatively, 
neonate cardiomyocytes treated with plasma from patients 
with CHD (at baseline and after 1 year) showed obvious cell 
death with myocytes elongation, whereas myocytes treated by 
plasma from patients with NHD were morphologically intact 
(Figure 2, A–C).
The interactions between cardiac fibroblasts and cardiomy-
ocytes are essential for the progression of cardiac remodel-
ing. We detected that CHD is characterized by a proliferation 
of fibroblast at baseline (44.1%) and at 1 year (29.1%). In 
contrast, NHD reduced the proportion of proliferating fibro-
blasts from 45.4% (baseline) to 15.5% (NHD for 1 year). In 
addition, fibroblasts phenotype changed to myofibroblast 
with increased expression of α-SM actin (data not shown). 
of note, collagen III production was stimulated during CHD 
conditions, which was subsequently attenuated after conver-
sion to NHD (Figure 3).
NHD-Induced Gene Expression Changes in Cardiomyocytes
A priori, we targeted genes associated with fibroblast pro-
liferation and cardiomyocyte autophagy, necrosis, and apop-
tosis (Figure 3). Nocturnal home hemodialysis was associated 
with downregulation in Cdkn1c-2, Cdkn1a, FGF23, collagen 
3, and fibronectin, implicating that NHD is less fibrogenic 
compared with CHD. Intensification of dialysis dose did not 
modify consistently all genes associated with autophagy. In 
contrast, NHD is associated with downregulation of MyD88, 
Fas, and Bax.
Uremia-Induced Cardiomyocyte Apoptosis Through 
Activation of the Innate Immunity Pathway
We systematically analyzed the influence of conversion 
from CHD to NHD on MyD88 mediated pathway (Figure 4). 
At baseline, Traf6 and IRAK-4 were increased under CHD con-
dition. After 1 year of NHD, MyD88, Traf6, and IRAK-4 were 
reduced, whereas CHD did not modify the levels of these inter-
mediate activation nodes. Given that Hsps) are known to trigger 
MyD88 pathway, systematically, we examined Hsp27, Hsp60, 
Hsp70, and Hsp90 levels at baseline and after 1 year of CHD 
or NHD. of note, we observed that Hsp60 was increased at 
baseline and was reduced after conversion to NHD (Figure 5).
We also examined the levels of RIPK1 and RIPK3, two 
important nodes in the necroptosis pathway. Changes in dialy-
sis prescription did not alter the necroptosis pathway (Data not 
shown).
Discussion
Cardiovascular disease remains the leading cause of death 
in patients with ESRD. We have previously reported the 
gene signature of neonatal cardiomyocytes exposed to ure-
mic serum before and after conversion from CHD to NHD. 
The present results extend our observations by which uremia 
Figure 3. Gene expression patterns under different hemodialysis 
conditions. Cdkn1a, cyclin-dependent kinase inhibitor 1A; Cdkn1c, 
cyclin-dependent kinase inhibitor 1C; Fgf23, fibroblast growth fac-
tor 23; Atg, autophagy; CYLD, cylindromatosis; RIPK, receptor-
interacting protein kinase; Bax, Bcl2-associated X protein. *p < 
0.05; #p < 0.01. SE, standard error.
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is associated with cardiomyocyte apoptosis. of the potential 
candidate pathways, our data suggest that uremia is associ-
ated with activation of the ubiquitous toll-like receptors (TLR) 
and their downstream signaling pathways such as MyD88 and 
IRAK-4 leading to activation of innate immunity and apoptosis.
Inflammatory processes are fundamental to common cardio-
vascular diseases such as myocardial infarction, heart failure, 
and atherosclerosis. of the various inflammatory response 
models, the “Danger Model” proposes that the immune system 
response leads to harmful signals that cause tissue stress and 
ultimately destruction.17 Differences in the type of stress will 
determine the severity and extent of immunological response. 
Tissue stresses may include classical bacterial/viral infection, 
ischemia/reperfusion/oxygen-free radicals, mechanical injury, 
and transplantation. Classically, triggers to “danger signals” 
would include lipopolysaccharide and endogenously pro-
duced Hsp. The innate immune response to Danger Signals 
include the TLRs signaling pathways and their downstream 
signaling pathways such as MyD88 or IRAK-4 leading to ulti-
mately activation of transcription factors such as nuclear factor 
(NF)-κB and in turn mobilization of natural killer or dendritic 
cells and activation of acquired immunity.18
Recently, the cardiac relevance of the Danger Signal 
hypothesis was substantiated by Kim et al.19 These investiga-
tors treated adult rat cardiomyocytes with Hsp60. They dem-
onstrated that Hsp60-induced apoptosis of cardiomyocytes 
(as measured by increased caspase 3 activity and increased 
DNA fragmentation). In addition, apoptosis could be reduced 
by blocking antibodies to TLR4 and by NF-κB binding decoy. 
Clinically, circulating Hsp60 has been detected in plasma of 
patients with heart failure20 and represents a logical cardiac 
biomarker in high-risk population. Emerging data also sup-
port the importance of innate immunity in the pathogenesis of 
LVH. Toll-like receptor 4 antagonist (eritoran) was applied in a 
murine model after transverse aortic constriction. In compari-
son with the placebo arm, eritoran-treated animals had lower 
levels of interleukin-1 and interleukin-6.21 Left ventricular mass 
was also reduced in comparison with the placebo arm. Simi-
larly, MyD88 inhibitor was administered in murine model of 
acute myocardial infarction. MyD88 inhibition attenuated left 
ventricular dilatation and LVH, suggesting that Danger Signal 
Innate Immune Amplification System may be a viable target for 
treatment of LVH.22 In addition, the role of innate immunity has 
also emerged as a modulator of blood pressure and vascular 
injury.23 It is interesting to note that intensive hemodialysis has 
been consistently shown to improve blood pressure control, 
and it is tempting to speculate that the present results may be in 
part because of the improved blood pressure regulation.
Although both LVH and inflammation are known to con-
tribute to cardiovascular events in ESRD, it is unclear whether 
uremia per se may directly induce an inflammatory response. 
Toll-like receptor expression has also been studied in patients 
with ESRD. Gollapudi et al..24 examined blood samples from 
21 stable hemodialysis patients and 21 normal controls. The 
ESRD group exhibited significant upregulation of TLR2 and 
4 expressions on monocytes and significant upregulation of 
TLR4 on polymorphonuclear leukocytes. In addition, TLR4 
activity (as measured by lipopolysaccharide-stimulated cyto-
kine production) was higher in hemodialysis patients. Inter-
estingly, in a separate study, TLR4 expression in peripheral 
Figure 4. Innate immunity activation under different hemodialysis conditions. A: Representative Western blotting analysis is shown. 
B: Quantitative analysis is shown. MyD88, myeloid differentiation factor-88;, Traf6, tumor necrosis factor receptor–associated factor 6); 
IRAK-4, interleukin-1 receptor–associated kinase-4.
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blood monocytes was evaluated in 191 patients with ESRD.25 
TLR4 expression correlated significantly with age (r = 0.2, 
p = 0.007), CRP (r = 0.2, p = 0.008), and mean arterial blood 
pressure (r = −0.2, p = 0.02).
Along with cardiomyocyte death, fibrosis aggravates the 
extent of cardiac injury. External stress causes fibroblasts to 
change their phenotype,26,27 referred to as myofibroblasts 
because they express several SM markers including α-SM actin 
and SM22α.27–29 Myofibroblasts appear in the myocardium and 
believed to arise from resident interstitial and/or adventitial 
fibroblasts after injury26 but are not found in normal cardiac 
tissue.30 The disproportionate increase in collagen synthesis 
and deposition lead to stiffening of ventricles and impede both 
systolic and diastolic functions.31 In addition, fibrosis reduces 
capillary density and increases oxygen diffusion distance lead-
ing to hypoxia of cardiomyocytes, which is well recognized 
in ESRD.32,33 our group has previously reported amelioration 
in myocardial mechanics and ventricular stiffness before and 
after conversion from CHD to NHD.12
The present results will form the basis for a more robust 
examination of the notion that intensive hemodialysis may 
attenuate cardiac injury by decreasing the extent of cardiomyo-
cyte apoptosis and innate immunity activation. We will aim to 
use plasma collected from patients randomized to the Frequent 
Hemodialysis Network. Plasma from these patients will then 
be used to culture cardiomyocytes using the aforementioned 
techniques. We will aim to ascertain whether the degree of 
cardiomycoyte apoptosis and innate immunity activation is 
associated with the extent of left ventricular mass regression.
In summary, our pilot study is associated with a novel path-
way by which uremia may cause cardiac damage by immune 
amplification. our results suggest that uremia clearance 
directly impacts on cardiomyocyte apoptosis and myofibro-
blast transformation. The clinical relevance of innate immunity 
in patients with ESRD will be tested in a more robust manner 
using samples stored from randomized controlled trials.
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Figure 5. Differences in Hsp expression under different hemodialysis conditions. A: Representative Western blotting analysis is shown. 
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